TP53 and neoplasm: Nevertheless, by using isogenic p53 cell models, we found that the potentiating effects of G9a inhibition in the context of phleomycin were independent of p53 status, with tumour cells either proficient or deficient in p53 being similarly hypersensitised to phleomycin by G9a inhibition.